Identification of genes maintaining cancer growth is critical to our understanding of tumorigenesis. We report the first in vivo genetic screen of patient-derived tumors, using metastatic melanomas and targeting 236 chromatin genes by expression of specific shRNA libraries. Our screens revealed unprecedented numerosity of genes indispensable for tumor growth (~50% of tested genes) and unexpected functional heterogeneity among patients (<15% in common). Notably, these genes were not activated by somatic mutations in the same patients and are therefore distinguished from mutated cancer driver genes. We
Introduction
Overwhelming evidence suggests that tumor growth is sustained by gene mutations that confer a selective growth advantage to target cells (cancer driver mutations) (1) (2) (3) . The advent of next generation sequencing (NGS) has provided an initial view of the landscape of cancer-associated mutations (~400,000 non-synonymous mutations with ~18,000 genes involved), and has uncovered great inter-patient heterogeneity (10-200 mutations per tumor, with very few recurrent mutations) (1) (2) (3) .
Not all mutations, however, are drivers. The vast majority (>99.5%) has no effect on tumorigenesis, and accumulates passively during tumor progression (passenger mutations).
Putative driver mutations are currently identified by statistical methods (based on patterns and/or frequency of mutations), which allowed prioritization of a few hundreds (1) (2) (3) . Their mutational frequency is very low (~60% mutated in <1% of patients), and, as a consequence, only <5% of patients can be treated with targeted therapies directed against mutated drivers (4) .
Identification of mutated drivers requires formal demonstration of their tumorigenic role under conditions of in vivo cancer growth. Unfortunately, however, this information is available for only a fraction of the mutated cancer genes. Loss-of-function experiments targeting multiple genes were extensively used to investigate tumor vulnerabilities in vivo, using either cancer cell lines or genetically-engineered tumors which, however, do not reflect the genetic diversity of human malignancies (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) .
Here we report the first genetic screen performed on human tumors grown in vivo. We used metastatic malignant melanomas, rapidly growing tumors with a 10-year survival rate of <10%. Around 50% of patients carry mutations of BRAF and can be treated with BRAF inhibitors. Strikingly, these drugs induce objective clinical responses in ~50% of patients.
However, virtually every patient eventually experience disease progression during treatment, due to the emergence of resistant clones carrying secondary mutations, or activation of compensatory signaling pathways (15, 16) . Thus, there is an urgent need to identify new cancer drivers and related signaling pathways, to exploit novel approaches of treatment in melanoma.
Results

Generation of patient-derived xenografts (PDXs) of metastatic melanomas.
For the genetic screens, we used patient-derived xenografts (PDXs) of metastatic melanoma, obtained by injecting patient-derived bioptic samples (Table S1) mutations at codon 600 and 3 NRAS-mutations at codon 61 (Table S1 ). PDX1 and PDX2 samples were phenotypically indistinguishable from the original patients' tumors, as evaluated by histopathology (Hematoxylin and Eosin staining; not shown) and melanomamarker (S100, HMB-45, Melan-A, CD271 and MITF) analyses ( Figure S1 ).
To ensure that our PDXs also retained genomic features of the original tumors, we compared whole-exome sequencing data of patients' tissues and corresponding PDX1s/PDX2s of three patients (two NRAS-mutated: MM13 and MM16; one BRAFmutated: MM27). The vast majority of mutations (SNVs/InDels) found in the patients' melanomas were also present in the corresponding PDXs (>98.8% in PDX1s and >97.3% in PDX2s; Figure S2A ), including relevant melanoma driver mutations (e.g., NRAS, BRAF, RAC1, CDKN2A, NF1; not shown). Allele frequency of individual SNVs/InDels in the patients' samples was highly variable (5%-60%) and, most notably, was maintained in the PDX1 and PDX2 tumors ( Figure S2B ), suggesting that the growth pattern of the various cell subclones composing each tumor is retained after transplantation in NSGs. Thus, melanomas PDXs fully recapitulate both genomic and biological complexity of the patient tumors.
Unbiased in vivo pooled shRNA screens in metastatic melanoma patients
One critical feature for the feasibility of in vivo genetic screens is the number of transduced tumor cells that grow after transplantation in NSG mice (tumor-initiating cells; TICs), which must be sufficiently large to support the molecular complexity of the library (library representation). The challenge in achieving this condition is due to the fact that TICs might represent a fraction of the entire tumor population and that TIC frequencies (and their growth potential) can vary within the multiple subclones that characterize each tumor. TIC frequency is relatively high in melanoma samples (17) 6 cannot be directly quantified. Thus, we analysed the degree of biological complexity indirectly, by genetically marking each tumor and testing its capacity to retain the same molecular complexity after transplantation into NSG mice. Cells from MM13, MM16 and MM27 PDX1 tumors were infected with a non-targeting lentiviral library containing ~12,500 plasmids with unique barcodes (BC) (13K library) and no-associated shRNAs, under experimental conditions that allow high representation of individual BCs (~400 transplanted cells/BC) and one retroviral integration per cell (see Methods). Transduced cells were then injected into NSG mice to obtain PDX2s. Genomic DNA (gDNA) from PDX1 cells and PDX2 tumors was then analysed by NGS to assess absolute and relative representations of each BC ( Figure 1A ). We found the entire molecular repertoire of BCs in all the analysed samples (not shown). The relative representation of individual BCs was highly comparable in the two PDX2 tumor replicates ( Figure 1B , left panels) and the ratio between individual BC reads in the two PDX2 tumors and in the PDX1 cells (log2(ratio)) followed a symmetric distribution, with a median that was centered at around zero ( Figure   1B , right panels). Thus tumors were capable of supporting the molecular complexity of a 13K library in vivo, despite their heterogeneous growth properties, with less than 5% of BCs depleted more than 3-fold.
We then screened the three melanomas under the same experimental conditions using a lentiviral shRNA library targeting 236 epigenetic modulators (10 different shRNAs/gene) and 4 screening control genes (a total complexity of 2,410 shRNAs; Figure 1A and Table   S2 ). For all three patients, NGS analyses revealed full representation of the library complexity (≥99% of the 2,410 BCs; not shown) and high correlation (R=0.81, 0.55 and 0.70; Figure 1C , left panels) in PDX2 tumor replicates. The log 2 (ratio) distribution of the BCs was markedly shifted toward a negative value (medians of -2,72, -2.61 and -0.76, respectively, in patients MM13, MM16 and MM27; Figure 1C , right panels), suggesting that the library inhibited melanoma growth in vivo. Notably, in each of the three screens, the positive (PSMA1, KIF11 and RPL30) and the neutral (Renilla luciferase -Luc) controls behaved as expected (Table S2A) .
Genes were scored as candidate hits when >6 different shRNAs were found depleted during melanoma growth. Depleted shRNAs were identified by applying the median of the log 2 (ratio) distribution as cut-off threshold ( Figure 1C , lower panels). These analyses led to the identification of 117 genes that were consistently depleted in at least one of the three melanomas ( Figure 1D ; Table S2A ). The depleted genes were equally distributed among the different functional classes of epigenetic modifiers included in the library (Table S2B ).
Analyses of the depleted genes among different melanomas, however, showed a high degree of patient specificity: 66, 69 and 55 genes were counter-selected, respectively, in the MM13, MM16 and MM27 melanomas, with only 17 (~15%) in common ( Figure 1D and Table S2A ).
Validation of the epigenetic shRNA screens
We chose 14 hits with different biological effects in the three samples (Table S2A) shRNAs ( Figure 2A ).
Finally, we validated 4 hits (BAZ1B, SMARCA4, CHD4 and KMT2D genes, Table S2A Research. To investigate biological mechanisms of the in vivo tumor growth inhibition, shRNAtransduced melanoma cells were analysed in vitro for their proliferation and migration properties, two key features of the in vivo growth potential of melanomas (23) . The effect on proliferation was variable in the different patients, yet all together modest (from 0% to a max of 50% reduction compared to shLuc; Figure 2C ). On the contrary, the effect on migration was very strong (50-90% reduction for all silenced genes), with the expected exception of KMT2D-silencing in the MM27 BRAF-mutated melanoma ( Figure 2D ). The result was further strengthened by the overexpression of SMARCA4 and CHD4 in shortterm cultures of MM16 PDX2 cells ( Figure S4A-F) , which significantly induced cell migration. Together, these results suggest that tumor growth inhibition by silencing of the four epigenetic targets is closely associated with inhibition of cell migration.
KMT2D activates a migratory transcriptional program in NRAS-mutated melanomas
We then investigated the molecular mechanisms underlying the biological effects of To investigate whether the 103-genes KMT2D-signature is specific to NRAS-mutated patients, we analysed the expression of 52 (including 29 migratory genes) in NRAS-mutated and BRAF-mutated melanomas upon KMT2D-silencing (Table S5 ). The 52 genes followed the same pattern of regulation in the three NRAS-mutated melanomas, while their regulation was non-uniform in the three BRAF-mutated samples ( Figure 4C ). These data demonstrate that KMT2D supports a transcriptional program in the NRAS melanomas, which mainly involves genes responsible for cell migration.
KMT2D regulates enhancer activity in the melanoma patients
KMT2D is a member of the Histone-lysine N-methyltransferase 2 (KMT2) family of proteins that methylate lysine 4 on the histone H3 tail (H3K4) and induce genome accessibility and transcription. KMT2D predominantly promotes H3K4 mono-methylation (H3K4me1) at adipocyte-, myocyte-and macrophage-specific enhancers, and transcriptome changes during adipogenesis and trans-differentiation of pre-adipocytes into myocytes (20, 22, 28) .
Thus, we investigated if the effect of KMT2D on transcription is associated with its monomethyltransferase activity on enhancers, using the MM16 NRAS-mutated melanoma. To map KMT2D genomic sites, shKMT2D-or control shLuc-expressing cells were analysed by ChIP sequencing (ChIP-seq) using anti-KMT2D antibodies. ChIP-seq data revealed 14,258 KMT2D sites in control cells, 6,545 of which were absent (no peak call) in the KMT2D-silenced cells ( Figure 5A ). Strikingly, the vast majority of the shKMT2D-sensitive peaks (89%; n=5,794) mapped to either intergenic regions (~50%) or gene bodies (~50%), while most of the KMT2D sites present in both control and KMTD2-silenced cells mapped to the Transcriptional Start Site (TSS) of known genes (82%) ( Figure 5A ). Thus, our experimental conditions of KMT2D depletion (~50% reduction; Figure S3C ) induced a specific loss of KMT2D genomic sites at regions outside gene promoters. To map KMT2D-bound active enhancers, we first selected genomic regions with H3K4me1-positivity, H3K27Ac-positivity and high H3K4me1 to H3K4me3 ratio (28) .
ChIP-seq analyses revealed 20,714 active enhancers in MM16 PDX2 cells ( Figure 5B ).
Finally, we intersected the KMT2D sites and active enhancers and identified 2,832 KMT2D-bound active enhancers ( Figure 5B ). Thus, in MM16 melanoma, ~50% of the shKMT2D-sensitive KMT2D peaks which map outside the gene promoters, were found at active enhancers.
We then investigated the effect of KMT2D expression on H3K4me1 and H3K27Ac levels in the KMT2D-bound active enhancers. Upon KMT2D-silencing, the KMT2D-bound active enhancers showed reduction of H3K4me1 (~50%) or H3K27Ac (~40%, >1. reduction. This is probably due to the distinct kinetics followed by H3K4me1 and H3K27Ac during enhancer activation/inactivation (29, 30) . Thus, to evaluate the effects of KMT2D binding on enhancer activity, we considered, as read out, H3K27Ac levels.
Together, these data demonstrate that KMT2D-silencing in MM16 cells leads to inactivation of a subset of the KMT2D-bound active enhancers, that we named "KMT2D-dependent enhancers" (H3K27Ac >1.5 fold reduction; n=1,041) ( Figure 5D and Figure 6A ), and suggest that this might be due to a KMT2D-dependent reduction in H3K4me1 deposition at the same sites. The lack of any effect of KMT2D on the remaining KMT2D-bound active enhancers (those showing no reduction of H3K27Ac, named "KMT2D-independent enhancers", n=897; Figure 6A ) might be due to the presence on the same enhancers of other mono-methyltransferases, such as KMT2C, which is also expressed in MM16 cells (data not shown).
Notably, the number of the KMT2D-bound and the KMT2D-dependent enhancers in MM16 PDX cells did not increase significantly when all the KMT2D peaks were Figure 6B) and found that the number of KMT2D-bound active enhancers or KMT2D-dependent enhancers in common among MM16, MM13 and MM27 was very low, suggesting a specific KMT2D-enhancer-regulation pattern among different tumors.
KMT2D deregulates specific enhancers and target genes in NRAS-melanomas
We then investigated whether the effect of KMT2D on enhancer activity is mechanistically linked to its effects on gene-specific transcription. Enhancers influence expression of their targets over large distances (tens to several hundreds of kilobases), and different mechanisms -DNA looping, tracking/scanning of intervening sequences -have been proposed to explain how they associate with target TSSs (31) . As an initial assessment of the relationship of TSSs of KMT2D down-regulated genes with KMT2D-dependent enhancers, we measured their physical distance in linear genomic sequence, and compared this value to the distance between TSSs of KMT2D down-regulated genes with KMT2D-independent enhancers in all three melanomas. We found that the KMT2D-dependent enhancers are in greater proximity to the closest down-regulated genes ( Figures 6A,C) , suggesting that KMT2D-dependent modifications at chromatin of distal enhancers are mechanistically linked to variations in expression of target genes.
To test this hypothesis, we investigated whether patterns of enhancer activation by KMT2D correlate with selectivity of its transcriptional effect. To this end, we first investigated whether the TSSs of 64 NRAS-specific down-regulated genes ( Figure 4A 
Strikingly, the distances between the same genes and the closest KMT2D-dependent enhancers in MM27 (2.9 and 1.4 Mb; Figure 6D ) were 10-and 20-fold greater than in MM16 and MM13, respectively (Figures 6D), suggesting that these enhancers might not be involved in the regulation of the NRAS-down modulated genes. We then investigated the effect of the binding of KMT2D to the identified KMT2D-dependent enhancer sites on the expression of the closest putative target genes. For this purpose, we selected two KMT2D-dependent enhancers showing strong H3K27Ac drop (2.2 fold reduction; E1: 18 kb upstream of the MFGE8 TSS, and E2: 113 kb upstream of the RPL39L TSS; Figure 7A-B) among the closest to the 29 MM16 down-regulated genes ( Figure 6D ), and one control enhancer (E3, Figure 7C ) mapping 24 kb upstream of ITPKB TSS. This enhancer, in fact, is KMT2D-bound but shows no significant H3K27Ac reduction upon shKMT2D ( Figure 7D ).
To inhibit KMT2D activity at the selected enhancer regions, we used the dCas9-KRAB fusion protein with two different single guide RNAs: sgRNA #1a or #1b, #2a or #2b, #3a or #3b, targeting E1, E2, and E3, respectively ( Figure 7D ). Krüppel associated box (KRAB) has been reported to efficiently silence transcription by recruiting Kap1 and HP1 proteins (32) and allows genome-specific targeting when fused to catalytically inactive Cas9 (dCas9). Short-term cultures of MM16 PDX2 cells were independently infected with sgRNAs and then transduced with dCas9-KRAB construct. Strikingly, four days after dCas9-KRAB transduction, targeting of the E1 or E2 enhancers reduced significantly the expression of MFGE8 and RPL39L, respectively, while no ITPKB down-regulation was observed upon targeting of E3 ( Figure 7D ). MFGE8 and RPL39L down-regulation was also observed upon targeting of the KMT2D-dependent enhancers E4 or E5 (mapping farther away from MFGE8 and RPL39L TSS) with the corresponding sgRNAs (#4a or #4b and #5a or #5b, respectively; Figure 7D ). Together, these data show that specificity of the 
transcriptional effect of KMT2D correlates with physical proximity of KMT2D-dependent enhancers to the target genes.
Discussion
We demonstrated that in vivo genetic screens of patients' tumors are feasible, at least using shRNA libraries of relatively high complexity (2,410 shRNAs) and metastatic melanomas.
Melanomas are among the tumors with the highest frequency of TICs, which is a critical limiting factor of the in vivo screens. Our screening protocol, however, can sustain the high subclonal complexity of melanomas, suggesting that under the appropriate experimental conditions, biological complexity may not limit in vivo genetic screens of primary tumors.
In vivo genetic screens allow identification of genes indispensable for cancer maintenance in patient-derived tumors under in vivo conditions. This is significantly different from the currently used model systems, mainly cancer cell lines (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , and might provide novel insights into mechanisms of tumor maintenance.
Our screens revealed unprecedented numerosity and unexpected degree of functional heterogeneity among individual tumors. We screened 236 genes in three melanoma patients and identified around 60 critical genes per tumor, with only 17 (~15%) in common and a total of 117 involved (e.g. ~50% of all tested genes). We also compared the results obtained Indeed, the same melanomas were screened with shRNA libraries of metabolic genes and deubiquitinating enzymes/helicases (335 and 287 genes, respectively), which gave similar results (data not shown). Alternatively, the observed functional-complexity and patientheterogeneity might reflect multiple layers of adaptation of individual tumors to the continuously changing tumor environment or genomic context, with consequent activation of multiple and non-redundant signaling pathways and high frailty of the transformed phenotype. Notably, the identified melanoma hits do not appear to be activated by somatic mutations in our patients, despite epigenetic genes are frequently mutated in cancer, including melanomas (34, 35). The frequency of SNVs in the identified hits, in fact, was slightly lower than in the non-hits (Figures S8A, B) .
Genes carrying biological relevant mutations (cancer driver genes) (2) are considered the best candidates for the development of targeting drugs. Our data, however, suggest that somatically mutated genes are not necessarily the most critical genes for tumor maintenance, since virtually all the identified hits in our melanomas were not somatically mutated. This might have important clinical implications, since it would expand significantly the pool of druggable genes, and, for each patient, the number of critical genes for which a drug is available (actionable genes). For example, 10 of the melanoma essential genes that we have identified are indeed actionable ( Figure S8C ). This is particularly relevant for the NRAS-mutated melanomas, which currently have few treatment options (36) .
We investigated the biological and molecular mechanisms in tumorigenesis of KMT2D, one of the NRAS-melanoma essential genes that we have identified. KMT2D is frequently mutated in a variety of cancers (20) . Most cancer-associated KMT2D mutations are frame shift and nonsense alterations, suggesting that it functions as a tumor suppressor. Several lines of evidence, however, suggest that KMT2D might also exhibit oncogenic properties for various tumors. It is overexpressed in breast and colon carcinomas, where it is associated with poor prognosis, while its silencing significantly reduces migration in colorectal and breast cancer cell lines and growth in a mouse xenograft of bladder cancer (20) . We showed here that KMT2D-depletion reduces cell migration and inhibits in vivo growth of NRAS-mutated melanomas. Notably, KMT2D was found in its germ line configuration in the same patients, suggesting alternative mechanisms of KMT2D activation in these tumors.
We have initially investigated the consequences of KMT2D activation in NRAS-mutated melanomas. KMT2D is the major candidate enhancer H3K4me1 methyltransferase in mammals (22) . We showed that KMT2D-silencing leads to inactivation of a subset of KMT2D-bound enhancers (reduced H3K4me1 and H3K27Ac) and down-regulation of a subset of genes that are critical for cell migration, including MFGE8 and RPL39L. Downregulation of either gene in several cancer types, and in melanoma and breast carcinomas specifically, reduces cell migration, and their expression correlates with a more aggressive phenotype and unfavorable outcome in the patients (37) (38) (39) . Notably, KMT2D target genes Table S2 ) contains 2410 vectors, targeting 236 genes (10 different shRNAs per targeted gene), 3 positive controls (PSMA1, KIF11 and RPL30) and 1 neutral control (Luciferase).
80 pRSI vectors, each one expressing an shRNA associated to a unique BC (see Table S3 ), were purchased by Cellecta and either pooled together to obtain a small-scale shRNA library (80sh library) or used individually. 50 Scrambled (SCR) shRNAs were synthesized starting from sequences of the following genes: E.coli lactose operon (GenBankJ01636.1), trp operon (GenBankV00372.1) and kanamicin resistance (GenBankAJ002684.1); S.aureus chloramphenicol resistance (GenBankAB481130.1); vector pHV1249 ampicillin resistance (GenBankAF307748.1); Anabaena nitrogen fixation (GenBankJ05111.1); P.abies rubisco large subunit (GenBankX75478.1); C.arabica rubisco large subunit (GenBankAJ419827.1); S.cerevisiae genes ACH1 (Gene ID 852266), TPS1 (Gene ID 852423), PNC1 (Gene ID 852846), ILV1 (Gene ID 856819), YMC2 (Gene ID 852401). Each gene was divided in a pool of 21-bp oligonucleotides using the sliding window scan through the sequence. All sequences were aligned against human (hg18) and mouse (mm9) genomes using two aligner programs, Bowtie (40) and blastn. SCR shRNAs were selected among those sequences that do not align against human and mouse genomes using both aligner programs. In vitro studies. 5,000 PDX2 infected cells were incubated for 72 hr, and proliferation was measured by CellTiter-Glo assays (Promega). The migration assay was performed using 8.0µm pore size, fibronectin pre-coated, inserts in 24-well plates. Duplicates of 100,000 cells in serum-free medium were plated in the upper chamber and complete medium was added to the lower chamber. 
